Oculis Holding AG

NasdaqGM:OCS Stock Report

Market Cap: US$833.4m

Oculis Holding Management

Management criteria checks 2/4

Oculis Holding's CEO is Riad Sherif, appointed in Dec 2017, has a tenure of 8.58 years. directly owns 2.14% of the company’s shares, worth $17.82M. The average tenure of the management team and the board of directors is 2.4 years and 3.7 years respectively.

Key information

Riad Sherif

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure8.6yrs
CEO ownership2.1%
Management average tenure2.4yrs
Board average tenure3.7yrs

Recent management updates

Recent updates

Seeking Alpha • Jun 02

Oculis Holding: Study Setback For Eye Drop Therapy Suggests Hold Rating

Summary Oculis Holding AG shares plunged >35% after both Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema failed primary and key secondary endpoints. OCS-01 will not move forward for FDA filing in DME, undermining the company's main value driver and casting doubt on its near-term commercial prospects. Attention shifts to pipeline assets Licaminlimab (dry eye disease, Phase 3) and Privosegtor (optic neuropathies), but competitive and data risks remain significant. With $277.6m cash and a >$800m market cap, I remain on the sidelines, unconvinced of a 'Buy the Dip' opportunity until further clinical catalysts materialize. Read the full article on Seeking Alpha
Seeking Alpha • Jan 21

Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care

Summary Oculis' main value driver appears to be OCS-01, which targets a respectable $4 billion DME TAM with its non-invasive eye drops. Eye injections are tough on patients, so this bodes well for OCS-01. OCS-05 and OCS-02 also target interesting TAMs in neuro-ophthalmology and DMD. OCS’s cash runway should last until late 2026, but if they don’t generate an FDA-approved product soon, it could become an issue for shareholders. Still, I see a few catalysts with upcoming regulatory milestones, like an NDA for OCS-01 in Q1, that could help sustain OCS stock’s valuation. I recommend a DCA strategy because Oculis stock might consolidate after such an impressive rally recently. Read the full article on Seeking Alpha
Seeking Alpha • Nov 04

Oculis: Lack Of Coverage Only Real Risk For This Solid Company

Summary Oculis has multiple late-stage programs and catalysts. Trading volume is low, and there's hardly any coverage in the US. Barring the low liquidity, OCS looks attractive. Read the full article on Seeking Alpha

CEO

Riad Sherif (58 yo)

8.6yrs
Tenure

Dr. Riad Sherif, MD, MBA, has been the Chief Executive Officer and Director of Oculis Holding AG (formerly known as Oculis SA) since December 2017. He is Chief Executive Officer and Director of Oculis ehf....

Leadership Team

NamePositionTenureCompensationOwnership
Riad Sherif
CEO & Director8.6yrsno data2.14%
$ 17.8m
Sylvia Cheung
Chief Financial Officer5.8yrsno data0.13%
$ 1.1m
Gudrun Bachmann
Chief Technology Officer1.8yrsno datano data
Ramin Tadayoni
Chief Scientific Officer2.3yrsno datano data
Katie Kazem
Chief Legal Officerless than a yearno datano data
Virginia Dean
Chief Human Resources Officer2.4yrsno datano data
Páll Jóhannesson
Chief Business Officer5.8yrsno data0.42%
$ 3.5m
Rebecca Weil
Chief Commercial Officer2.8yrsno datano data
Snehal Shah
President of Research & Development2.3yrsno datano data
Sharon Klier
Chief Development Officer1.9yrsno datano data
Isabelle de Chambrier
Senior Vice President of Quality2.8yrsno datano data
2.4yrs
Average Tenure
54.5yo
Average Age

Experienced Management: OCS's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Riad Sherif
CEO & Director8.6yrsno data2.14%
$ 17.8m
Gregory Perry
Directorless than a yearno datano data
Eric Donnenfeld
Chair of Cornea Scientific Advisory Boardno datano datano data
Anthony Rosenberg
Independent Chairman8.3yrsno data0.20%
$ 1.6m
Christophe Baudouin
Member of Scientific Advisory Board3.7yrsno datano data
Peter Kaiser
Member of Scientific Advisory Board3.7yrsno datano data
Lionel Carnot
Independent Director8.6yrsno data0.15%
$ 1.3m
Quan Dong Nguyen
Member of Scientific Advisory Board3.7yrsno datano data
Robert Warner
Independent Director2.2yrsno data0.016%
$ 135.1k
Arshad Khanani
Chair of Retina Scientific Advisory Board & Independent Director3.7yrsno data0.018%
$ 148.8k
Anat Loewenstein
Member of Scientific Advisory Board3.7yrsno datano data
Pablo Villoslada
Member of Scientific Advisory Board3.7yrsno datano data
3.7yrs
Average Tenure
59yo
Average Age

Experienced Board: OCS's board of directors are considered experienced (3.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 05:17
End of Day Share Price 2026/07/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oculis Holding AG is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Jason Matthew GerberryBofA Global Research
Daniil GataulinChardan Capital Markets, LLC